Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer

Main Article Content

Anisha Patel
University of Texas MD Anderson Cancer Center, Houston, TX

Lucia Seminario-Vidal
H. Lee Moffitt Cancer Center, Tampa, FL

Keywords

Pharmacology, Alpelisib-Associated Rash, phosphoinositide 3-kinase inhibitor

Abstract

Abstract not available.

References

1. Blows FM, et al. PLoS Med. 2010;7(5):e1000279.

2. Cancer Genome Atlas Network. Nature. 2012;490(7418):61-70.

3. Mollon L, et al. AACR 2018. Poster 1207.

4. Mosele F, et al. Ann Oncol. 2020;31(3):377-386.

5. Sobhani N, et al. J Cell Biochem. 2018;119(6):4287-4292.

6. Piqray [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019.

7. André F, et al. N Engl J Med. 2019;380(20):1929-1940.

8. Schindler K, et al. J Clin Oncol. 2014;32:e20639.

9. Rugo HS, et al. Ann Oncol. 2020;31(8):1001-1010.

10. Rugo HS, et al. ASCO 2020. Abstract 1006 (oral).

11. Wang DG, et al. Breast Cancer Res Treat. 2020;183(1):227-237.

12. U.S. Department of Health and Human Services, NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 (CTCAE).

13. U.S. Department of Health and Human Services, NIH, National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03 (CTCAE).

14. Nunnery SE, Mayer IA. Ann Oncol. 2019;30(suppl 10):x21-x26.

15. Chia S, et al. Curr Oncol. 2015;22(1):33-48.

16. Balagula Y, et al. Cancer. 2012;118(20):5078-5083.

17. BC Cancer. Provincial Health Services Authority. http://www.bccancer.bc.ca/. Accessed August 31, 2020.

18. Tan AU, et al. Int J Womens Dermatol. 2017;4(2):56-71.

19. Tamez-Perez HL, et al. World J Diabetes. 2015;6(8):1073-1081.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.111

Article Details

How to Cite
Patel, A., & Seminario-Vidal, L. (2020). Incidence, Characteristics, and Management of Alpelisib-Associated Rash in Patients With Advanced Breast Cancer. SKIN The Journal of Cutaneous Medicine, 4(6), s111. https://doi.org/10.25251/skin.4.supp.111
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Dermatopharmacology
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.